Kinaxo Biotechnologies Enters Agreement with Takeda
""We consider this agreement with Takeda, the leading R&D-oriented pharmaceutical company of Japan, to be a major progress in the world-wide expansion of our business", said Dr. Andreas Jenne, tthe chief executive officer of Kinaxo. "We continue to demonstrate the validation of the KinaTor(TM) ttechnology by providing services to leading pharmaceutical and biotechnology companies, including Johnson& Johnson, Bayer-Schering, Takeda and UCB Pharma."
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!